Krystal Biotech (KRYS) Accumulated Expenses (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Accumulated Expenses data on file, last reported at $31.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 11.22% year-over-year to $31.2 million; the trailing twelve-month figure through Mar 2026 stood at $31.2 million (up 11.22% YoY), and the FY2025 full-year result was $39.8 million, down 32.61% from the prior year.
• Accumulated Expenses declined to $31.2 million in Q1 2026, from $39.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $59.0 million in Q4 2024 to a low of $17.9 million in Q2 2023.
• A 5-year average of $32.4 million and a median of $29.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 663.94% in 2022 and tumbled 42.12% in 2023, its largest moves.
• Tracing KRYS's Accumulated Expenses over 5 years: stood at $23.3 million in 2022, then retreated by 7.7% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then slumped by 32.61% to $39.8 million in 2025, then decreased by 21.52% to $31.2 million in 2026.
• Business Quant data shows KRYS's Accumulated Expenses at $31.2 million in Q1 2026, $39.8 million in Q4 2025, and $31.7 million in Q3 2025.